Atlas Compliance Blog

Latest insights and updates from Atlas Compliance

December 20, 2024

How to Address and Prevent FDA Form 483 Observations?

tl;dr: FDA Form 483 observations highlight GMP non-compliance during FDA inspections. Common issues include equipment, documentation, processes, training, and facility controls. Prevent them through proactive management, strong documentation, training, audits, and compliance tools. Atlas simplifies compliance by automating insights and improving inspection readiness. What Is FDA Form 483 Observations?  FDA Form 483 observations are official […]

Read More
December 17, 2024

Unexo’s Operations Questioned as FDA Lists 12 Compliance Issues 

tl;dr: Unexo, an over-the-counter drug manufacturer, recently faced scrutiny during an FDA inspection conducted from May 1, 2024, to May 14, 2024, led by inspectors Nicole Knowlton and Kellia Hicks. This inspection led to the Warning Letter by the USFDA ranging from inadequate documentation to improper facility maintenance. This article breaks down the key observations […]

Read More